You do not currently have access to this content.
Abstract. The overexpression of HER3 in solid tumors is associated with poor prognosis. Therapies developed to target HER3-mediated signaling are often associated with resistance over time, ...
Abstract. Activating mutations in the epidermal growth factor receptor (EGFR) gene occur in 10-20% of Caucasian and 40% of Asian non-small cell lung cancer (NSCLC) patients. Predominant ones among ...
Abstract 2395: DXC011, a novel dual-payload antibody-drug conjugate targeting folate receptor alpha.
Abstract. Folate Receptor alpha (FRα) is highly expressed in epithelial ovarian cancer and selected solid tumors, making it an attractive target for antibody-drug conjugates (ADCs). Although an ...
AbstractIntroduction:. Trophoblast cell-surface antigen 2 (Trop-2) has become an attractive antibody drug conjugate (ADC) target as it is expressed in multiple solid tumors. Sacituzumab govitecan (SG) ...
AbstractBackground:. Urothelial carcinoma (UC) affects over 600,000 patients worldwide annually, with the incidence rate increasing over the past decade. Metastatic urothelial carcinoma (mUC) has a ...
Cancer Res (2024) 84 (7_Supplement): ND08. The glycosphingolipid GD2 is a cell membrane component of a limited number of normal tissues including nerve cells, melanocytes or lymphocytes. However, in ...
CRISPR screens are a powerful discovery engine for biological research and have been extensively used for drug target discovery and validation. Pooled screens are advantageous because they can easily ...
Abstract. The identification of immunogenic cancer epitopes, including patient-specific neoepitopes and shared tumor-associated antigens (TAAs), is a critical foundation for advancing effective cancer ...
TenSixty Biosciences employs an innovative AI-enhanced multi-omics discovery framework to enable the development of next-generation antibody-drug conjugates (ADCs). This integrated approach identified ...
Background: GDF15 is overexpressed in solid tumors, with immunosuppressive effects on dendritic cells (DCs), T cells and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. AZD8853 ...
Around 75% of breast cancer (BC) patients have tumors expressing the treatment-predictive biomarker estrogen receptor α (ER) and are consequently offered endocrine therapy. One-third of these patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results